ArticleBMC immunology2026
Pretreatment immunoglobulin profiles and survival outcomes in hematologic malignancies and autoimmune cytopenias: a comparative cohort analysis.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Rethinking secondary immunodeficiency: a cross-domain pathway framework for risk stratification.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlterations in immunoglobulin levels are commonly observed in hematologic malignancies and immune-mediated cytopenias, reflecting underlying immune dysregulation. While the prognostic relevance of hypogammaglobulinemia (HGG) has been studied in chronic lymphocytic leukemia (CLL), comparable data across a broader range of hematologic diagnoses remain limited. This study aimed to conduct a comparative analysis of baseline immunoglobulin profiles (IgG, IgA, IgM, IgE) across a heterogeneous cohort of patients with NHL, CLL, HL, ITP, and AIHA. Our primary objective was to evaluate the disease-specific associations of these profiles with survival outcomes to identify diagnostic groups that benefit most from baseline immune profiling.
resultsA total of 779 patients were included: 294 with NHL, 220 with CLL, 106 with HL, 128 with ITP, and 31 with AIHA. Quantitative and categorical analyses demonstrated significant differences in immunoglobulin levels across disease groups. CLL patients exhibited the highest frequency of low immunoglobulin levels, particularly for IgM and IgA. Kaplan–Meier analysis revealed numerically shorter overall survival in patients with low pretreatment IgG levels, although this difference was not statistically significant in the pooled heterogeneous cohort (p = 0.119). However, this association was not confirmed in the overall multivariable Cox regression model. Subgroup analysis using diagnosis-specific Cox models identified normal/high IgG status as independently associated with improved survival in NHL (HR: 0.543; p = 0.017), but not in CLL, HL, ITP, or AIHA. Associations for IgA, IgM, and IgE with mortality were not evaluated in these diagnosis-specific models.
conclusionsWhile low pretreatment IgG levels were associated with poorer survival in the overall cohort on univariate analysis, this association was not significant in the multivariable model. However, subgroup analysis identified low IgG as an independent and significant predictor of mortality in patients with NHL, but not in other diagnoses. These findings highlight that the prognostic value of immunoglobulin profiling is highly disease-specific. Baseline IgG assessment appears most relevant for risk stratification in NHL. However, the use of all-cause mortality limits our ability to discern the specific mechanism (e.g., infection-related vs. disease-progression-related) underlying this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.